News
The first healthy volunteer has been dosed in a Phase 1 study of Cellarity's novel globin-switching therapy CLY-124 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback